ROIV Gains Momentum as Priovant’s Brepocitinib Shows Significant Phase 2 Efficacy in Cutaneous Sarcoidosis
Market Chameleon (Fri, 6-Feb 11:10 AM)
Brepocitinib Delivers Landmark Phase 2 Results in Cutaneous Sarcoidosis—Roivant Solidifies Late-Stage Pipeline Momentum
Market Chameleon (Fri, 6-Feb 7:56 AM)
